Restasis

Earth Day gives ODs a chance to promote green patient habits
Earth Day gives ODs a chance to promote green patient habits
Understanding the link between MGD and OSDMeibomian gland dysfunction (MGD) may be misdiagnosed. While MGD is one of the most common chronic ocular conditions, diagnosing MGD isn’t as simple as it seems.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
How digital device usage is affecting youthThe time we are spending on digital devices is on the rise, and it’s unlikely to slow down any time soon. With more and more apps, games, and social media options, we have all become more dependent on smartphones, tablets, and other electronic devices.
How to combat vernal keratoconjunctivitisIt is a precarious position considering the desire to find the perfect remedy— yet with vernal keratoconjunctivitis (VKC), there is no magic bullet.
Reduce dropout in patients with dry eye
When corneas go viral: Epidemic keratoconjunctivitis editionThe possibility that a given garden-variety case of viral conjunctivitis is a burgeoning epidemic keratoconjunctivitis (EKC) is enough to intimidate any physician.
Managing ocular surface disease in patients with glaucomaTreating ocular surface disease may have an impact on the effectiveness of glaucoma treatment. Inder Paul Singh, MD, offers some strategies used in practice.
Why accountable contact lens fitting mattersIn order to properly care for our contact lens patients, we have to take responsibility for the changes that are occurring in the tear film under the lens.
Shire's FDA-approved drug ends dry eye treatment drought
Shire's FDA-approved drug ends dry eye treatment droughtOphthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients—and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.